| Year |
Citation |
Score |
| 2024 |
Ricker CA, Meli K, Van Allen EM. Historical perspective and future directions: computational science in immuno-oncology. Journal For Immunotherapy of Cancer. 12. PMID 38191244 DOI: 10.1136/jitc-2023-008306 |
0.313 |
|
| 2023 |
Kamran SC, Zhou Y, Otani K, Drumm M, Otani Y, Wu S, Wu CL, Feldman AS, Wszolek M, Lee RJ, Saylor PJ, Lennerz J, Van Allen E, Willers H, Hong TS, et al. Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37870965 DOI: 10.1158/1078-0432.CCR-23-0792 |
0.301 |
|
| 2023 |
Hoffman SE, Dowrey TW, Villacorta Martin C, Bi K, Titchen B, Johri S, DelloStritto L, Patel M, Mackichan C, Inga S, Chen J, Grimaldi G, Napolitano S, Wakiro I, Wu J, ... ... Van Allen EM, et al. Intertumoral lineage diversity and immunosuppressive transcriptional programs in well-differentiated gastroenteropancreatic neuroendocrine tumors. Science Advances. 9: eadd9668. PMID 37756410 DOI: 10.1126/sciadv.add9668 |
0.319 |
|
| 2023 |
Doe-Tetteh SA, Camp SY, Reales D, Crowdis J, Noronha AM, Wolff B, Alano T, Galle J, Selcuklu SD, Viale A, Socci ND, Liu YL, Tew WP, Aghajanian C, Ladanyi M, ... ... Van Allen EM, et al. Overcoming barriers to tumor genomic profiling through direct-to-patient outreach. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36862133 DOI: 10.1158/1078-0432.CCR-22-3247 |
0.363 |
|
| 2022 |
Crowdis J, Balch S, Sterlin L, Thomas BS, Camp SY, Dunphy M, Anastasio E, Shah S, Damon AL, Ramos R, Sosa DM, Small IK, Tomson BN, Nguyen CM, McGillicuddy M, ... ... Van Allen EM, et al. A patient-driven clinicogenomic partnership for metastatic prostate cancer. Cell Genomics. 2. PMID 36177448 DOI: 10.1016/j.xgen.2022.100169 |
0.597 |
|
| 2022 |
Zhou M, Ko M, Hoge AC, Luu K, Liu Y, Russell ML, Hannon WW, Zhang Z, Carrot-Zhang J, Beroukhim R, Van Allen EM, Choudhury AD, Nelson PS, Freedman M, Taplin ME, et al. Patterns of structural variation define prostate cancer across disease states. Jci Insight. PMID 35943799 DOI: 10.1172/jci.insight.161370 |
0.306 |
|
| 2022 |
Barroso-Sousa R, Forman J, Collier K, Weber ZT, Jammihal TR, Kao KZ, Richardson ET, Keenan T, Cohen O, Manos MP, Brennick RC, Ott PA, Hodi FS, Dillon DA, Attaya V, ... ... Van Allen EM, et al. Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. Jco Precision Oncology. 6: e2100413. PMID 35797509 DOI: 10.1200/PO.21.00413 |
0.559 |
|
| 2022 |
Church AJ, Corson LB, Kao PC, Imamovic-Tuco A, Reidy D, Doan D, Kang W, Pinto N, Maese L, Laetsch TW, Kim A, Colace SI, Macy ME, Applebaum MA, Bagatell R, ... ... Van Allen E, et al. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nature Medicine. PMID 35739269 DOI: 10.1038/s41591-022-01856-6 |
0.313 |
|
| 2022 |
Ricciuti B, Wang X, Alessi JV, Rizvi H, Mahadevan NR, Li YY, Polio A, Lindsay J, Umeton R, Sinha R, Vokes NI, Recondo G, Lamberti G, Lawrence M, Vaz VR, ... ... Van Allen EM, et al. Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. Jama Oncology. PMID 35708671 DOI: 10.1001/jamaoncol.2022.1981 |
0.319 |
|
| 2022 |
Hwang JH, Arafeh R, Seo JH, Baca SC, Ludwig M, Arnoff TE, Sawyer L, Richter C, Tape S, Bergom HE, McSweeney S, Rennhack JP, Klingenberg SA, Cheung ATM, Kwon J, ... ... Van Allen EM, et al. CREB5 reprograms FOXA1 nuclear interactions to promote resistance to androgen receptor targeting therapies. Elife. 11. PMID 35550030 DOI: 10.7554/eLife.73223 |
0.669 |
|
| 2022 |
Gil Del Alcazar CR, Trinh A, Aleckovic M, Rojas Jimenez E, Harper NW, Oliphant MU, Xie S, Krop ED, Lulseged B, Murphy KC, Keenan TE, Van Allen EM, Tolaney SM, Freeman GJ, Dillon DA, et al. Insights into immune escape during tumor evolution and response to immunotherapy using a rat model of breast cancer. Cancer Immunology Research. PMID 35446942 DOI: 10.1158/2326-6066.CIR-21-0804 |
0.314 |
|
| 2022 |
Dietlein F, Wang AB, Fagre C, Tang A, Besselink NJM, Cuppen E, Li C, Sunyaev SR, Neal JT, Van Allen EM. Genome-wide analysis of somatic noncoding mutation patterns in cancer. Science (New York, N.Y.). 376: eabg5601. PMID 35389777 DOI: 10.1126/science.abg5601 |
0.357 |
|
| 2022 |
Stover EH, Oh C, Keskula P, Choudhury AD, Tseng YY, Adalsteinsson VA, Lohr JG, Thorner AR, Ducar M, Kryukov GV, Ha G, Rosenberg M, Freeman SS, Zhang Z, Wu X, ... Van Allen EM, et al. Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples. The Prostate. PMID 35084050 DOI: 10.1002/pros.24305 |
0.571 |
|
| 2022 |
Bakouny Z, Sadagopan A, Ravi P, Metaferia NY, Li J, AbuHammad S, Tang S, Denize T, Garner ER, Gao X, Braun DA, Hirsch L, Steinharter JA, Bouchard G, Walton E, ... ... Van Allen EM, et al. Integrative clinical and molecular characterization of translocation renal cell carcinoma. Cell Reports. 38: 110190. PMID 34986355 DOI: 10.1016/j.celrep.2021.110190 |
0.311 |
|
| 2021 |
Kehl KL, Xu W, Gusev A, Bakouny Z, Choueiri TK, Riaz IB, Elmarakeby H, Van Allen EM, Schrag D. Artificial intelligence-aided clinical annotation of a large multi-cancer genomic dataset. Nature Communications. 12: 7304. PMID 34911934 DOI: 10.1038/s41467-021-27358-6 |
0.345 |
|
| 2021 |
De Sarkar N, Dasgupta S, Chatterjee P, Coleman I, Ha G, Ang LS, Kohlbrenner EA, Frank SB, Nunez TA, Salipante SJ, Corey E, Morrissey C, Van Allen E, Schweizer MT, Haffner MC, et al. Genomic attributes of homology-directed DNA repair deficiency in metastatic prostate cancer. Jci Insight. 6. PMID 34877933 DOI: 10.1172/jci.insight.152789 |
0.373 |
|
| 2021 |
Cejas P, Xie Y, Font-Tello A, Lim K, Syamala S, Qiu X, Tewari AK, Shah N, Nguyen HM, Patel RA, Brown L, Coleman I, Hackeng WM, Brosens L, Dreijerink KMA, ... ... Van Allen EM, et al. Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer. Nature Communications. 12: 5775. PMID 34599169 DOI: 10.1038/s41467-021-26042-z |
0.744 |
|
| 2021 |
Bekele RT, Samant AS, Nassar AH, So J, Garcia EP, Curran CR, Hwang JH, Mayhew DL, Nag A, Thorner AR, Börcsök J, Sztupinszki Z, Pan CX, Bellmunt J, Kwiatkowski DJ, ... ... Van Allen EM, et al. RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics. The Journal of Clinical Investigation. PMID 34554931 DOI: 10.1172/JCI147849 |
0.366 |
|
| 2021 |
Keenan TE, Guerriero JL, Barroso-Sousa R, Li T, O'Meara T, Giobbie-Hurder A, Tayob N, Hu J, Severgnini M, Agudo J, Vaz-Luis I, Anderson L, Attaya V, Park J, Conway J, ... ... Van Allen EM, et al. Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. Nature Communications. 12: 5563. PMID 34548479 DOI: 10.1038/s41467-021-25769-z |
0.319 |
|
| 2021 |
Tewari AK, Cheung ATM, Crowdis J, Conway JR, Camp SY, Wankowicz SA, Livitz DG, Park J, Lis RT, Bosma-Moody A, He MX, AlDubayan SH, Zhang Z, McKay RR, Leshchiner I, ... ... Van Allen EM, et al. Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer. Cell Reports. 36: 109665. PMID 34496240 DOI: 10.1016/j.celrep.2021.109665 |
0.537 |
|
| 2021 |
Barroso-Sousa R, Keenan TE, Li T, Tayob N, Trippa L, Pastorello RG, Richardson Iii ET, Dillon D, Amoozgar Z, Overmoyer B, Schnitt SJ, Winer EP, Mittendorf EA, Van Allen E, Duda DG, et al. Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study. Npj Breast Cancer. 7: 110. PMID 34433812 DOI: 10.1038/s41523-021-00287-9 |
0.34 |
|
| 2021 |
Liu D, Lin JR, Robitschek EJ, Kasumova GG, Heyde A, Shi A, Kraya A, Zhang G, Moll T, Frederick DT, Chen YA, Wang S, Schapiro D, Ho LL, Bi K, ... ... Van Allen EM, et al. Evolution of delayed resistance to immunotherapy in a melanoma responder. Nature Medicine. PMID 33941922 DOI: 10.1038/s41591-021-01331-8 |
0.345 |
|
| 2021 |
Bi K, He MX, Bakouny Z, Kanodia A, Napolitano S, Wu J, Grimaldi G, Braun DA, Cuoco MS, Mayorga A, DelloStritto L, Bouchard G, Steinharter J, Tewari AK, Vokes NI, ... ... Van Allen EM, et al. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Cancer Cell. PMID 33711272 DOI: 10.1016/j.ccell.2021.02.015 |
0.301 |
|
| 2021 |
He MX, Cuoco MS, Crowdis J, Bosma-Moody A, Zhang Z, Bi K, Kanodia A, Su MJ, Ku SY, Garcia MM, Sweet AR, Rodman C, DelloStritto L, Silver R, Steinharter J, ... ... Van Allen EM, et al. Transcriptional mediators of treatment resistance in lethal prostate cancer. Nature Medicine. PMID 33664492 DOI: 10.1038/s41591-021-01244-6 |
0.326 |
|
| 2021 |
Bakouny Z, Braun DA, Shukla SA, Pan W, Gao X, Hou Y, Flaifel A, Tang S, Bosma-Moody A, He MX, Vokes N, Nyman J, Xie W, Nassar AH, Abou Alaiwi S, ... ... Van Allen EM, et al. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nature Communications. 12: 808. PMID 33547292 DOI: 10.1038/s41467-021-21068-9 |
0.679 |
|
| 2021 |
Tewari A, Van Allen E. Integrated Analysis of Germ Cell Tumors. Methods in Molecular Biology (Clifton, N.J.). 2195: 181-187. PMID 32852765 DOI: 10.1007/978-1-0716-0860-9_13 |
0.383 |
|
| 2020 |
Mateo J, McKay R, Abida W, Aggarwal R, Alumkal J, Alva A, Feng F, Gao X, Graff J, Hussain M, Karzai F, Montgomery B, Oh W, Patel V, Rathkopf D, ... ... Van Allen E, et al. Accelerating precision medicine in metastatic prostate cancer. Nature Cancer. 1: 1041-1053. PMID 34258585 DOI: 10.1038/s43018-020-00141-0 |
0.326 |
|
| 2020 |
Cormedi MCV, Van Allen EM, Colli LM. Predicting immunotherapy response through genomics. Current Opinion in Genetics & Development. 66: 1-9. PMID 33307238 DOI: 10.1016/j.gde.2020.11.004 |
0.36 |
|
| 2020 |
Börcsök J, Sztupinszki Z, Bekele R, Gao SP, Diossy M, Samant AS, Dillon KM, Tisza V, Spisák S, Rusz O, Csabai I, Pappot H, Frazier ZJ, Konieczkowski DJ, Liu D, ... ... Van Allen EM, et al. Identification of a synthetic lethal relationship between nucleotide excision repair (NER) deficiency and irofulven sensitivity in urothelial cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33208343 DOI: 10.1158/1078-0432.CCR-20-3316 |
0.327 |
|
| 2020 |
Cheng ML, Donoghue MTA, Audenet F, Wong NC, Pietzak EJ, Bielski CM, Isharwal S, Iyer G, Funt S, Bagrodia A, Bajorin DF, Reuter VE, Eng J, Joseph G, Bourque C, ... ... Van Allen E, et al. Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs. Jco Precision Oncology. 4. PMID 33163850 DOI: 10.1200/PO.20.00166 |
0.317 |
|
| 2020 |
Rusert JM, Juarez EF, Brabetz S, Jensen J, Garancher A, Chau LQ, Tacheva-Grigorova SK, Wahab S, Udaka YT, Finlay D, Seker-Cin H, Reardon B, Gröbner S, Serrano J, Ecker J, ... ... Van Allen EM, et al. Functional precision medicine identifies new therapeutic candidates for medulloblastoma. Cancer Research. PMID 33046443 DOI: 10.1158/0008-5472.CAN-20-1655 |
0.323 |
|
| 2020 |
Font-Tello A, Kesten N, Xie Y, Taing L, Varešlija D, Young LS, Hamid AA, Van Allen EM, Sweeney CJ, Gjini E, Lako A, Hodi FS, Bellmunt J, Brown M, Cejas P, et al. FiTAc-seq: fixed-tissue ChIP-seq for H3K27ac profiling and super-enhancer analysis of FFPE tissues. Nature Protocols. PMID 32591768 DOI: 10.1038/S41596-020-0340-6 |
0.452 |
|
| 2020 |
Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Arnon L, Zimmer L, Gutzmer R, Satzger I, Loquai C, Grabbe S, Vokes N, Margolis CA, Conway J, He MX, ... ... Van Allen EM, et al. Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nature Medicine. PMID 32561875 DOI: 10.1038/S41591-020-0975-4 |
0.44 |
|
| 2020 |
Braun DA, Hou Y, Bakouny Z, Ficial M, Sant' Angelo M, Forman J, Ross-Macdonald P, Berger AC, Jegede OA, Elagina L, Steinharter J, Sun M, Wind-Rotolo M, Pignon JC, Cherniack AD, ... ... Van Allen EM, et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nature Medicine. PMID 32472114 DOI: 10.1038/S41591-020-0839-Y |
0.301 |
|
| 2020 |
Abou Alaiwi S, Nassar AH, Xie W, Bakouny Z, Berchuck JE, Braun DA, Baca SC, Nuzzo PV, Flippot R, Mouhieddine TH, Spurr LF, Li YY, Li T, Flaifel A, Steinharter JA, ... ... Van Allen EM, et al. Mammalian SWI/SNF complex genomic alterations and immune checkpoint blockade in solid tumors. Cancer Immunology Research. PMID 32321774 DOI: 10.1158/2326-6066.Cir-19-0866 |
0.723 |
|
| 2020 |
Rafiei S, Fitzpatrick K, Liu D, Cai MY, Elmarakeby HA, Park J, Ricker C, Kochupurakkal BS, Choudhury AD, Hahn WC, Balk SP, Hwang JH, Van Allen EM, Mouw KW. ATM Loss Confers Greater Sensitivity to ATR Inhibition than PARP Inhibition in Prostate Cancer. Cancer Research. PMID 32127357 DOI: 10.1158/0008-5472.Can-19-3126 |
0.348 |
|
| 2020 |
Barroso-Sousa R, Keenan TE, Pernas S, Exman P, Jain E, Garrido-Castro AC, Hughes ME, Bychkovsky B, Umeton R, Files JL, Lindeman NI, MacConaill LE, Hodi FS, Krop I, Dillon DA, ... ... Van Allen EM, et al. Tumor mutational burden and alterations as molecular correlates of response to PD-1/L1 blockade in metastatic triple-negative breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32019858 DOI: 10.1158/1078-0432.Ccr-19-3507 |
0.609 |
|
| 2020 |
Dietlein F, Weghorn D, Taylor-Weiner A, Richters A, Reardon B, Liu D, Lander ES, Van Allen EM, Sunyaev SR. Identification of cancer driver genes based on nucleotide context. Nature Genetics. PMID 32015527 DOI: 10.1038/S41588-019-0572-Y |
0.314 |
|
| 2019 |
Vokes NI, Liu D, Ricciuti B, Jimenez-Aguilar E, Rizvi H, Dietlein F, He MX, Margolis CA, Elmarakeby HA, Girshman J, Adeni A, Sanchez-Vega F, Schultz N, Dahlberg S, Zehir A, ... ... Van Allen EM, et al. Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. Jco Precision Oncology. 3. PMID 31832578 DOI: 10.1200/PO.19.00171 |
0.348 |
|
| 2019 |
Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Amon L, Zimmer L, Gutzmer R, Satzger I, Loquai C, Grabbe S, Vokes N, Margolis CA, Conway J, He MX, ... ... Van Allen EM, et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nature Medicine. PMID 31792460 DOI: 10.1038/S41591-019-0654-5 |
0.537 |
|
| 2019 |
Li H, Bullock K, Gurjao C, Braun D, Shukla SA, Bossé D, Lalani AA, Gopal S, Jin C, Horak C, Wind-Rotolo M, Signoretti S, McDermott DF, Freeman GJ, Van Allen EM, et al. Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nature Communications. 10: 4346. PMID 31554815 DOI: 10.1038/S41467-019-12361-9 |
0.621 |
|
| 2019 |
Gurjao C, Liu D, Hofree M, AlDubayan SH, Wakiro I, Su MJ, Felt K, Gjini E, Brais LK, Rotem A, Rosenthal MH, Rozenblatt-Rosen O, Rodig S, Ng K, Van Allen EM, et al. Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair Deficient Colorectal Cancer. Cancer Immunology Research. PMID 31217164 DOI: 10.1158/2326-6066.Cir-18-0683 |
0.383 |
|
| 2019 |
Amin-Mansour A, George S, Sioletic S, Carter SL, Rosenberg M, Taylor-Weiner A, Stewart C, Chevalier A, Seepo S, Tracy A, Getz G, Hornick JL, Nucci MR, Quade B, Demetri GD, ... ... Van Allen EM, et al. Genomic evolutionary patterns of leiomyosarcoma and liposarcoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31164371 DOI: 10.1158/1078-0432.Ccr-19-0271 |
0.419 |
|
| 2019 |
Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, Montgomery B, Pritchard C, Morrissey C, Barbieri CE, Beltran H, ... ... Van Allen EM, et al. Publisher Correction: The long tail of oncogenic drivers in prostate cancer. Nature Genetics. PMID 31152158 DOI: 10.1038/S41588-019-0451-6 |
0.453 |
|
| 2019 |
Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, Cieslik M, Benelli M, Robinson D, Van Allen EM, Sboner A, Fedrizzi T, Mosquera JM, Robinson BD, De Sarkar N, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 31061129 DOI: 10.1073/pnas.1902651116 |
0.334 |
|
| 2019 |
Keenan TE, Burke KP, Van Allen EM. Genomic correlates of response to immune checkpoint blockade. Nature Medicine. 25: 389-402. PMID 30842677 DOI: 10.1038/s41591-019-0382-x |
0.335 |
|
| 2018 |
Nassar AH, Lundgren K, Pomerantz M, Van Allen E, Harshman L, Choudhury AD, Preston MA, Steele GS, Mouw KW, Wei XX, McGregor BA, Choueiri TK, Bellmunt J, Kwiatkowski DJ, Sonpavde GP. Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked. Jco Precision Oncology. 2. PMID 33604498 DOI: 10.1200/PO.18.00013 |
0.325 |
|
| 2018 |
Hamid AA, Gray KP, Shaw G, MacConaill LE, Evan C, Bernard B, Loda M, Corcoran NM, Van Allen EM, Choudhury AD, Sweeney CJ. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. European Urology. PMID 30553611 DOI: 10.1016/j.eururo.2018.11.045 |
0.367 |
|
| 2018 |
Conway JR, Kofman E, Mo SS, Elmarakeby H, Van Allen E. Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine. Genome Medicine. 10: 93. PMID 30497521 DOI: 10.1186/s13073-018-0605-7 |
0.359 |
|
| 2018 |
Jerby-Arnon L, Shah P, Cuoco MS, Rodman C, Su MJ, Melms JC, Leeson R, Kanodia A, Mei S, Lin JR, Wang S, Rabasha B, Liu D, Zhang G, Margolais C, ... ... Van Allen EM, et al. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 175: 984-997.e24. PMID 30388455 DOI: 10.1016/J.Cell.2018.09.006 |
0.533 |
|
| 2018 |
Bellmunt J, Lalani AA, Jacobus S, Wankowicz SA, Polacek L, Takeda DY, Harshman LC, Wagle N, Moreno I, Lundgren K, Bossé D, Van Allen EM, Choueiri TK, Rosenberg JE. Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. British Journal of Cancer. PMID 30220708 DOI: 10.1038/S41416-018-0261-0 |
0.546 |
|
| 2018 |
Miao D, Margolis CA, Vokes NI, Liu D, Taylor-Weiner A, Wankowicz SM, Adeegbe D, Keliher D, Schilling B, Tracy A, Manos M, Chau NG, Hanna GJ, Polak P, Rodig SJ, ... ... Van Allen EM, et al. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nature Genetics. PMID 30150660 DOI: 10.1038/S41588-018-0200-2 |
0.393 |
|
| 2018 |
Sheng W, LaFleur MW, Nguyen TH, Chen S, Chakravarthy A, Conway JR, Li Y, Chen H, Yang H, Hsu PH, Van Allen EM, Freeman GJ, De Carvalho DD, He HH, Sharpe AH, et al. LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade. Cell. PMID 29937226 DOI: 10.1016/J.Cell.2018.05.052 |
0.327 |
|
| 2018 |
Sowalsky AG, Ye H, Bhasin M, Van Allen EM, Loda M, Lis RT, Montaser-Kouhsari L, Calagua C, Ma F, Russo JW, Schaefer RJ, Voznesensky OS, Zhang Z, Bubley GJ, Montgomery B, et al. Neoadjuvant-intensive androgen deprivation therapy selects for prostate tumor foci with diverse subclonal oncogenic alterations. Cancer Research. PMID 29921690 DOI: 10.1158/0008-5472.Can-18-0610 |
0.336 |
|
| 2018 |
Viswanathan SR, Ha G, Hoff AM, Wala JA, Carrot-Zhang J, Whelan CW, Haradhvala NJ, Freeman SS, Reed SC, Rhoades J, Polak P, Cipicchio M, Wankowicz SA, Wong A, Kamath T, ... ... Van Allen EM, et al. Structural Alterations Driving Castration-Resistant Prostate Cancer Revealed by Linked-Read Genome Sequencing. Cell. PMID 29909985 DOI: 10.1016/J.Cell.2018.05.036 |
0.325 |
|
| 2018 |
Shukla SA, Bachireddy P, Schilling B, Galonska C, Zhan Q, Bango C, Langer R, Lee PC, Gusenleitner D, Keskin DB, Babadi M, Mohammad A, Gnirke A, Clement K, Cartun ZJ, ... Van Allen EM, et al. Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. Cell. PMID 29656892 DOI: 10.1016/J.Cell.2018.03.026 |
0.53 |
|
| 2018 |
Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, Ng PK, Jeong KJ, Cao S, Wang Z, Gao J, ... ... Van Allen EM, et al. Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell. 173: 371-385.e18. PMID 29625053 DOI: 10.1016/J.Cell.2018.02.060 |
0.388 |
|
| 2018 |
Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, ... ... Van Allen EM, et al. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 173: 321-337.e10. PMID 29625050 DOI: 10.1016/J.Cell.2018.03.035 |
0.374 |
|
| 2018 |
Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, Han GC, Coleman I, Montgomery B, Pritchard C, Morrissey C, Barbieri CE, Beltran H, ... ... Van Allen EM, et al. The long tail of oncogenic drivers in prostate cancer. Nature Genetics. PMID 29610475 DOI: 10.1038/S41588-018-0078-Z |
0.556 |
|
| 2018 |
Edelman G, Rodon J, Lager J, Castell C, Jiang J, Van Allen EM, Wagle N, Lindeman NI, Sholl LM, Shapiro GI. Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors. The Oncologist. PMID 29593099 DOI: 10.1634/Theoncologist.2017-0691 |
0.516 |
|
| 2018 |
AlDubayan SH, Giannakis M, Moore ND, Han GC, Reardon B, Hamada T, Mu XJ, Nishihara R, Qian Z, Liu L, Yurgelun MB, Syngal S, Garraway LA, Ogino S, Fuchs CS, ... Van Allen EM, et al. Inherited DNA-Repair Defects in Colorectal Cancer. American Journal of Human Genetics. PMID 29478780 DOI: 10.1016/J.Ajhg.2018.01.018 |
0.488 |
|
| 2018 |
Hazar-Rethinam M, Kleyman M, Han GC, Liu D, Ahronian LG, Shahzade HA, Chen L, Parikh AR, Allen JN, Clark JW, Kwak EL, Faris JE, Murphy JE, Hong TS, Van Seventer EE, ... ... Van Allen EM, et al. Convergent therapeutic strategies to overcome the heterogeneity of acquired resistance in BRAFV600E colorectal cancer. Cancer Discovery. PMID 29431697 DOI: 10.1158/2159-8290.Cd-17-1227 |
0.338 |
|
| 2018 |
Miao D, Margolis CA, Gao W, Voss MH, Li W, Martini DJ, Norton C, Bossé D, Wankowicz SM, Cullen D, Horak C, Wind-Rotolo M, Tracy A, Giannakis M, Hodi FS, ... ... Van Allen EM, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science (New York, N.Y.). PMID 29301960 DOI: 10.1126/Science.Aan5951 |
0.312 |
|
| 2017 |
Han GC, Hwang J, Wankowicz SAM, Zhang Z, Liu D, Cibulskis C, Gaviola GC, Ghazikhanian V, McKay RR, Bubley GJ, Carter SL, Balk SP, Hahn WC, Taplin ME, Van Allen EM. Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer. Jco Precision Oncology. 1. PMID 32913968 DOI: 10.1200/PO.17.00140 |
0.327 |
|
| 2017 |
Liu D, Abbosh P, Keliher D, Reardon B, Miao D, Mouw K, Weiner-Taylor A, Wankowicz S, Han G, Teo MY, Cipolla C, Kim J, Iyer G, Al-Ahmadie H, Dulaimi E, ... ... Van Allen EM, et al. Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nature Communications. 8: 2193. PMID 29259186 DOI: 10.1038/S41467-017-02320-7 |
0.595 |
|
| 2017 |
Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, Gydush G, Reed SC, Rotem D, Rhoades J, Loginov D, Livitz D, Rosebrock D, Leshchiner I, Kim J, ... ... Van Allen EM, et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nature Communications. 8: 1324. PMID 29109393 DOI: 10.1038/S41467-017-00965-Y |
0.708 |
|
| 2017 |
Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, He MX, Walker W, Zhang G, Tian T, Cheng C, ... ... Van Allen EM, et al. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discovery. PMID 29101162 DOI: 10.1158/2159-8290.Cd-17-0833 |
0.518 |
|
| 2017 |
Kim JW, Abudayyeh OO, Yeerna H, Yeang CH, Stewart M, Jenkins RW, Kitajima S, Konieczkowski DJ, Medetgul-Ernar K, Cavazos T, Mah C, Ting S, Van Allen EM, Cohen O, Mcdermott J, et al. Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States. Cell Systems. 5: 105-118.e9. PMID 28837809 DOI: 10.1016/J.Cels.2017.08.002 |
0.505 |
|
| 2017 |
Giltnane JM, Hutchinson KE, Stricker TP, Formisano L, Young CD, Estrada MV, Nixon MJ, Du L, Sanchez V, Ericsson PG, Kuba MG, Sanders ME, Mu XJ, Van Allen EM, Wagle N, et al. Genomic profiling of ER(+) breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Science Translational Medicine. 9. PMID 28794284 DOI: 10.1126/Scitranslmed.Aai7993 |
0.682 |
|
| 2017 |
McGraw SA, Garber J, Jänne PA, Lindeman N, Oliver N, Sholl LM, Van Allen EM, Wagle N, Garraway LA, Joffe S, Gray SW. The fuzzy world of precision medicine: deliberations of a precision medicine tumor board. Personalized Medicine. 14: 37-50. PMID 28757884 DOI: 10.2217/Pme-2016-0074 |
0.647 |
|
| 2017 |
Johnson CP, Kim IK, Esmaeli B, Amin-Mansour A, Treacy DJ, Carter SL, Hodis E, Wagle N, Seepo S, Yu X, Lane AM, Gragoudas ES, Vazquez F, Nickerson E, Cibulskis K, ... ... Van Allen EM, et al. Systematic genomic and translational efficiency studies of uveal melanoma. Plos One. 12: e0178189. PMID 28594900 DOI: 10.1371/Journal.Pone.0178189 |
0.648 |
|
| 2017 |
Liu D, Vokes NI, Van Allen EM. Toward Molecularly Driven Precision Medicine in Lung Adenocarcinoma. Cancer Discovery. 7: 555-557. PMID 28576842 DOI: 10.1158/2159-8290.Cd-17-0355 |
0.334 |
|
| 2017 |
Huang FW, Mosquera JM, Garofalo A, Oh C, Baco M, Amin-Mansour A, Rabasha B, Bahl S, Mullane SA, Robinson BD, Aldubayan S, Khani F, Karir B, Kim E, Chimene-Weiss J, ... ... Van Allen EM, et al. Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations. Cancer Discovery. PMID 28515055 DOI: 10.1158/2159-8290.Cd-16-0960 |
0.541 |
|
| 2017 |
George S, Miao D, Demetri GD, Adeegbe D, Rodig SJ, Shukla S, Lipschitz M, Amin-Mansour A, Raut CP, Carter SL, Hammerman P, Freeman GJ, Wu CJ, Ott PA, Wong KK, ... Van Allen EM, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 46: 197-204. PMID 28228279 DOI: 10.1016/J.Immuni.2017.02.001 |
0.314 |
|
| 2017 |
Ghazani AA, Oliver NM, St Pierre JP, Garofalo A, Rainville IR, Hiller E, Treacy DJ, Rojas-Rudilla V, Wood S, Bair E, Parello M, Huang F, Giannakis M, Wilson FH, Stover EH, ... ... Van Allen EM, et al. Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 28125075 DOI: 10.1038/Gim.2016.191 |
0.665 |
|
| 2016 |
Taylor-Weiner A, Zack T, O'Donnell E, Guerriero JL, Bernard B, Reddy A, Han GC, AlDubayan S, Amin-Mansour A, Schumacher SE, Litchfield K, Turnbull C, Gabriel S, Beroukhim R, Getz G, ... ... Van Allen EM, et al. Genomic evolution and chemoresistance in germ-cell tumours. Nature. 540: 114-118. PMID 27905446 DOI: 10.1038/Nature20596 |
0.317 |
|
| 2016 |
Gibson WJ, Ruan DT, Paulson VA, Barletta JA, Hanna GJ, Kraft S, Calles A, Nehs MA, Moore FD, Taylor-Weiner A, Wala JA, Zack TI, Lee TC, Fennessy FM, Alexander EK, ... ... Van Allen E, et al. Genomic heterogeneity and exceptional response to dual pathway inhibition in anaplastic thyroid cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27797976 DOI: 10.1158/1078-0432.Ccr-16-2154-T |
0.531 |
|
| 2016 |
Giannakis M, Mu XJ, Shukla SA, Qian ZR, Cohen O, Nishihara R, Bahl S, Cao Y, Amin-Mansour A, Yamauchi M, Sukawa Y, Stewart C, Rosenberg M, Mima K, Inamura K, ... ... Van Allen EM, et al. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Reports. 17: 1206. PMID 27760322 DOI: 10.1016/J.Celrep.2016.10.009 |
0.451 |
|
| 2016 |
Braun DA, Burke KP, Van Allen EM. Genomic Approaches to Understanding Response and Resistance to Immunotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27698000 DOI: 10.1158/1078-0432.Ccr-16-0066 |
0.346 |
|
| 2016 |
De Velasco G, Miao DD, Voss MH, Hakimi AA, Hsieh JJ, Tannir NM, Tamboli P, Appleman LJ, Rathmell WK, Van Allen E, Choueiri TK. Tumor mutational load and immune parameters across metastatic Renal Cell Carcinoma (mRCC) risk groups. Cancer Immunology Research. PMID 27538576 DOI: 10.1158/2326-6066.Cir-16-0110 |
0.3 |
|
| 2016 |
Garofalo A, Sholl L, Reardon B, Taylor-Weiner A, Amin-Mansour A, Miao D, Liu D, Oliver N, MacConaill L, Ducar M, Rojas-Rudilla V, Giannakis M, Ghazani A, Gray S, Janne P, ... ... Van Allen EM, et al. The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. Genome Medicine. 8: 79. PMID 27460824 DOI: 10.1186/S13073-016-0333-9 |
0.689 |
|
| 2016 |
Pritchard CC, Mateo J, Walsh MF, De Sarkar N, Abida W, Beltran H, Garofalo A, Gulati R, Carreira S, Eeles R, Elemento O, Rubin MA, Robinson D, Lonigro R, Hussain M, ... ... Van Allen EM, et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. The New England Journal of Medicine. PMID 27433846 DOI: 10.1056/Nejmoa1603144 |
0.503 |
|
| 2016 |
Fay AP, de Velasco G, Ho TH, Van Allen EM, Murray B, Albiges L, Signoretti S, Hakimi AA, Stanton ML, Bellmunt J, McDermott DF, Atkins MB, Garraway LA, Kwiatkowski DJ, Choueiri TK. Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. Journal of the National Comprehensive Cancer Network : Jnccn. 14: 820-4. PMID 27407122 DOI: 10.6004/Jnccn.2016.0086 |
0.501 |
|
| 2016 |
Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, Hansel D, Kwiatkowski D, O'Donnell M, Rosenberg J, Svatek R, Abrams JS, Al-Ahmadie H, Apolo AB, Bellmunt J, ... ... Van Allen E, et al. Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer. 2: 165-202. PMID 27376138 DOI: 10.3233/BLC-160053 |
0.311 |
|
| 2016 |
Liu D, Plimack ER, Hoffman-Censits J, Garraway LA, Bellmunt J, Van Allen E, Rosenberg JE. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. Jama Oncology. PMID 27310333 DOI: 10.1001/Jamaoncol.2016.1056 |
0.419 |
|
| 2016 |
Miao D, Van Allen EM. Genomic determinants of cancer immunotherapy. Current Opinion in Immunology. 41: 32-38. PMID 27254251 DOI: 10.1016/j.coi.2016.05.010 |
0.395 |
|
| 2016 |
Giannakis M, Mu XJ, Shukla SA, Qian ZR, Cohen O, Nishihara R, Bahl S, Cao Y, Amin-Mansour A, Yamauchi M, Sukawa Y, Stewart C, Rosenberg M, Mima K, Inamura K, ... ... Van Allen EM, et al. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Reports. PMID 27149842 DOI: 10.1016/J.Celrep.2016.03.075 |
0.573 |
|
| 2016 |
Tirosh I, Izar B, Prakadan SM, Wadsworth MH, Treacy D, Trombetta JJ, Rotem A, Rodman C, Lian C, Murphy G, Fallahi-Sichani M, Dutton-Regester K, Lin JR, Cohen O, Shah P, ... ... Van Allen EM, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science (New York, N.Y.). 352: 189-196. PMID 27124452 DOI: 10.1126/Science.Aad0501 |
0.506 |
|
| 2016 |
Kim J, Mouw KW, Polak P, Braunstein LZ, Kamburov A, Tiao G, Kwiatkowski DJ, Rosenberg JE, Van Allen EM, D'Andrea AD, Getz G. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nature Genetics. PMID 27111033 DOI: 10.1038/Ng.3557 |
0.315 |
|
| 2016 |
Kim JW, Botvinnik OB, Abudayyeh O, Birger C, Rosenbluh J, Shrestha Y, Abazeed ME, Hammerman PS, DiCara D, Konieczkowski DJ, Johannessen CM, Liberzon A, Alizad-Rahvar AR, Alexe G, Aguirre A, ... ... Van Allen EM, et al. Characterizing genomic alterations in cancer by complementary functional associations. Nature Biotechnology. PMID 27088724 DOI: 10.1038/Nbt.3527 |
0.541 |
|
| 2016 |
McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, Watkins TB, Shafi S, Murugaesu N, Mitter R, Akarca AU, ... ... Van Allen EM, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science (New York, N.Y.). PMID 26940869 DOI: 10.1126/Science.Aaf1490 |
0.537 |
|
| 2016 |
Mullane SA, Van Allen EM. Precision medicine for advanced prostate cancer. Current Opinion in Urology. 26: 231-9. PMID 26909474 DOI: 10.1097/MOU.0000000000000278 |
0.311 |
|
| 2016 |
Gray SW, Park ER, Najita J, Martins Y, Traeger L, Bair E, Gagne J, Garber J, Jänne PA, Lindeman N, Lowenstein C, Oliver N, Sholl L, Van Allen EM, Wagle N, et al. Oncologists' and cancer patients' views on whole-exome sequencing and incidental findings: results from the CanSeq study. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 26866579 DOI: 10.1038/Gim.2015.207 |
0.655 |
|
| 2016 |
Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, Marotz C, Giannopoulou E, Chakravarthi BV, Varambally S, Tomlins SA, Nanus DM, Tagawa ST, Van Allen EM, Elemento O, et al. Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nature Medicine. 22: 298-305. PMID 26855148 DOI: 10.1038/Nm.4045 |
0.562 |
|
| 2015 |
Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, et al. Integrative Clinical Genomics of Advanced Prostate Cancer. Cell. 162: 454. PMID 28843286 DOI: 10.1016/J.Cell.2015.06.053 |
0.521 |
|
| 2015 |
Kryukov GV, Bielski C, Samocha K, Fromer M, Seepo S, Gentry C, Neale B, Garraway LA, Sweeney CJ, Taplin ME, Van Allen EM. Genetic effect of chemotherapy exposure in children of testicular cancer survivors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26631610 DOI: 10.1158/1078-0432.Ccr-15-2317 |
0.451 |
|
| 2015 |
Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, Van Allen EM, Lawrence MS, Horowitz PM, Cibulskis K, Ligon KL, Tabernero J, Seoane J, Martinez-Saez E, Curry WT, et al. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discovery. PMID 26410082 DOI: 10.1158/2159-8290.Cd-15-0369 |
0.479 |
|
| 2015 |
Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, Sucker A, Hillen U, Geukes Foppen MH, Goldinger SM, Utikal J, Hassel JC, Weide B, Kaehler KC, Loquai C, et al. Genomic correlates of response to CTLA4 blockade in metastatic melanoma. Science (New York, N.Y.). PMID 26359337 DOI: 10.1126/Science.Aad0095 |
0.571 |
|
| 2015 |
Van Allen EM, Lui VW, Egloff AM, Goetz EM, Li H, Johnson JT, Duvvuri U, Bauman JE, Stransky N, Zeng Y, Gilbert BR, Pendleton KP, Wang L, Chiosea S, Sougnez C, et al. Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. Jama Oncology. 1: 238-44. PMID 26181029 DOI: 10.1001/Jamaoncol.2015.34 |
0.624 |
|
| 2015 |
Tolaney SM, Tan S, Guo H, Barry W, Van Allen E, Wagle N, Brock J, Larrabee K, Paweletz C, Ivanova E, Janne P, Overmoyer B, Wright JJ, Shapiro GI, Winer EP, et al. Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer. Investigational New Drugs. PMID 26123926 DOI: 10.1007/S10637-015-0269-8 |
0.559 |
|
| 2015 |
Van Allen EM, Golay HG, Liu Y, Koyama S, Wong K, Taylor-Weiner A, Giannakis M, Harden M, Rojas-Rudilla V, Chevalier A, Thai T, Lydon C, Mach S, Avila AG, Wong JA, et al. Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation. Cancer Immunology Research. PMID 26014096 DOI: 10.1158/2326-6066.Cir-15-0024 |
0.485 |
|
| 2015 |
Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 161: 1215-28. PMID 26000489 DOI: 10.1016/J.Cell.2015.05.001 |
0.567 |
|
| 2015 |
Hsieh CL, Botta G, Gao S, Li T, Van Allen EM, Treacy DJ, Cai C, He HH, Sweeney CJ, Brown M, Balk SP, Nelson PS, Garraway LA, Kantoff PW. PLZF, a Tumor Suppressor Genetically Lost in Metastatic Castration-Resistant Prostate Cancer, Is a Mediator of Resistance to Androgen Deprivation Therapy. Cancer Research. 75: 1944-8. PMID 25808865 DOI: 10.1158/0008-5472.Can-14-3602 |
0.669 |
|
| 2015 |
Van Allen EM, Garraway LA, Rosenberg JE. Re: Floris H. Groenendijk, Jeroen de Jong, Elisabeth E. Fransen van de Putte, et al. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.01.014. European Urology. 68: e31-2. PMID 25770487 DOI: 10.1016/j.eururo.2015.02.044 |
0.443 |
|
| 2015 |
Wilson FH, Johannessen CM, Piccioni F, Tamayo P, Kim JW, Van Allen EM, Corsello SM, Capelletti M, Calles A, Butaney M, Sharifnia T, Gabriel SB, Mesirov JP, Hahn WC, Engelman JA, et al. A functional landscape of resistance to ALK inhibition in lung cancer. Cancer Cell. 27: 397-408. PMID 25759024 DOI: 10.1016/J.Ccell.2015.02.005 |
0.475 |
|
| 2015 |
Ahronian LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE, Godfrey JT, Nishimura K, Lynch KD, Mermel CH, Lockerman EL, Kalsy A, Gurski JM, Bahl S, Anderka K, et al. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Cancer Discovery. 5: 358-67. PMID 25673644 DOI: 10.1158/2159-8290.Cd-14-1518 |
0.706 |
|
| 2014 |
Perry JA, Kiezun A, Tonzi P, Van Allen EM, Carter SL, Baca SC, Cowley GS, Bhatt AS, Rheinbay E, Pedamallu CS, Helman E, Taylor-Weiner A, McKenna A, DeLuca DS, Lawrence MS, et al. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proceedings of the National Academy of Sciences of the United States of America. 111: E5564-73. PMID 25512523 DOI: 10.1073/Pnas.1419260111 |
0.785 |
|
| 2014 |
Giannakis M, Hodis E, Jasmine Mu X, Yamauchi M, Rosenbluh J, Cibulskis K, Saksena G, Lawrence MS, Qian ZR, Nishihara R, Van Allen EM, Hahn WC, Gabriel SB, Lander ES, Getz G, et al. RNF43 is frequently mutated in colorectal and endometrial cancers. Nature Genetics. 46: 1264-6. PMID 25344691 DOI: 10.1038/Ng.3127 |
0.503 |
|
| 2014 |
Wagle N, Grabiner BC, Van Allen EM, Amin-Mansour A, Taylor-Weiner A, Rosenberg M, Gray N, Barletta JA, Guo Y, Swanson SJ, Ruan DT, Hanna GJ, Haddad RI, Getz G, Kwiatkowski DJ, et al. Response and acquired resistance to everolimus in anaplastic thyroid cancer. The New England Journal of Medicine. 371: 1426-33. PMID 25295501 DOI: 10.1056/Nejmoa1403352 |
0.688 |
|
| 2014 |
Van Allen EM, Mouw KW, Kim P, Iyer G, Wagle N, Al-Ahmadie H, Zhu C, Ostrovnaya I, Kryukov GV, O'Connor KW, Sfakianos J, Garcia-Grossman I, Kim J, Guancial EA, Bambury R, et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discovery. 4: 1140-53. PMID 25096233 DOI: 10.1158/2159-8290.Cd-14-0623 |
0.651 |
|
| 2014 |
Yuan Y, Van Allen EM, Omberg L, Wagle N, Amin-Mansour A, Sokolov A, Byers LA, Xu Y, Hess KR, Diao L, Han L, Huang X, Lawrence MS, Weinstein JN, Stuart JM, et al. Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nature Biotechnology. 32: 644-52. PMID 24952901 DOI: 10.1038/Nbt.2940 |
0.703 |
|
| 2014 |
Van Allen EM, Wagle N, Stojanov P, Perrin DL, Cibulskis K, Marlow S, Jane-Valbuena J, Friedrich DC, Kryukov G, Carter SL, McKenna A, Sivachenko A, Rosenberg M, Kiezun A, Voet D, et al. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nature Medicine. 20: 682-8. PMID 24836576 DOI: 10.1038/Nm.3559 |
0.681 |
|
| 2014 |
Lohr JG, Adalsteinsson VA, Cibulskis K, Choudhury AD, Rosenberg M, Cruz-Gordillo P, Francis JM, Zhang CZ, Shalek AK, Satija R, Trombetta JJ, Lu D, Tallapragada N, Tahirova N, Kim S, ... ... Van Allen EM, et al. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nature Biotechnology. 32: 479-84. PMID 24752078 DOI: 10.1038/Nbt.2892 |
0.42 |
|
| 2014 |
Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, Stewart M, Choueiri TK, Gandhi L, Cleary JM, Elfiky AA, Taplin ME, Stack EC, Signoretti S, Loda M, et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discovery. 4: 546-53. PMID 24625776 DOI: 10.1158/2159-8290.Cd-13-0353 |
0.673 |
|
| 2014 |
Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, Rosenberg M, Goetz EM, Sullivan RJ, Farlow DN, Friedrich DC, Anderka K, Perrin D, Johannessen CM, McKenna A, et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discovery. 4: 61-8. PMID 24265154 DOI: 10.1158/2159-8290.Cd-13-0631 |
0.663 |
|
| 2014 |
Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, Place CS, Taylor-Weiner A, Whittaker S, Kryukov GV, Hodis E, Rosenberg M, Mckenna A, Cibulskis K, Farlow D, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma Cancer Discovery. 4: 94-109. PMID 24265153 DOI: 10.1158/2159-8290.Cd-13-0617 |
0.68 |
|
| 2014 |
Rosenberg JE, Bambury RM, Van Allen EM, Drabkin HA, Lara PN, Harzstark AL, Wagle N, Figlin RA, Smith GW, Garraway LA, Choueiri T, Erlandsson F, Laber DA. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma Investigational New Drugs. 32: 178-187. PMID 24242861 DOI: 10.1007/S10637-013-0045-6 |
0.689 |
|
| 2013 |
Berg JS, Amendola LM, Eng C, Van Allen E, Gray SW, Wagle N, Rehm HL, DeChene ET, Dulik MC, Hisama FM, Burke W, Spinner NB, Garraway L, Green RC, Plon S, et al. Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 15: 860-7. PMID 24195999 DOI: 10.1038/Gim.2013.133 |
0.637 |
|
| 2013 |
Tarczy-Hornoch P, Amendola L, Aronson SJ, Garraway L, Gray S, Grundmeier RW, Hindorff LA, Jarvik G, Karavite D, Lebo M, Plon SE, Van Allen E, Weck KE, White PS, Yang Y. A survey of informatics approaches to whole-exome and whole-genome clinical reporting in the electronic health record. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 15: 824-32. PMID 24071794 DOI: 10.1038/Gim.2013.120 |
0.426 |
|
| 2013 |
Baca SC, Prandi D, Lawrence MS, Mosquera JM, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M, Van Allen E, Kryukov GV, Sboner A, Theurillat JP, Soong TD, et al. Punctuated evolution of prostate cancer genomes. Cell. 153: 666-77. PMID 23622249 DOI: 10.1016/J.Cell.2013.03.021 |
0.741 |
|
| 2013 |
Van Allen EM, Wagle N, Levy MA. Clinical analysis and interpretation of cancer genome data. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 1825-33. PMID 23589549 DOI: 10.1200/Jco.2013.48.7215 |
0.621 |
|
| 2013 |
Whittaker SR, Theurillat JP, Van Allen E, Wagle N, Hsiao J, Cowley GS, Schadendorf D, Root DE, Garraway LA. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discovery. 3: 350-62. PMID 23288408 DOI: 10.1158/2159-8290.Cd-12-0470 |
0.668 |
|
| 2012 |
Van Allen EM, Pomerantz M. Moving toward personalized medicine in castration-resistant prostate cancer. The Urologic Clinics of North America. 39: 483-90. PMID 23084525 DOI: 10.1016/j.ucl.2012.07.005 |
0.317 |
|
| 2012 |
Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N, Nickerson E, Chae SS, Boysen G, Auclair D, Onofrio RC, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nature Genetics. 44: 685-9. PMID 22610119 DOI: 10.1038/Ng.2279 |
0.739 |
|
| Show low-probability matches. |